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Malignant tumours are the foremost complications of 
immunosuppressive treatment. They are a major chal-
lenge for organ transplant recipients and their treating 
physicians. This paper reviews the aetiology and current 
treatment of an unusual neuroendocrine skin cancer, 
Merkel cell carcinoma (MCC), caused by a Merkel cell 
polyomavirus infection. MCC occurs more frequently 
than expected in immunosuppressed subjects, especially 
in organ transplant recipients. The current literature 
comprises reports of 79 organ transplant recipients with 
MCC. The risk of MCC in organ transplant recipients is 
increased up to 66–182-fold compared with the general 
population. In addition to the increased risk of develo-
ping MCC, immunosuppressed individuals have poorer 
MCC-specific survival. The aim of this review article is 
to familiarize organ transplant doctors with this unique 
and clinically challenging skin cancer, and to provide re-
cent data on the diagnosis and current treatment recom-
mendations for an immunosuppressed population. Key 
words: neuroendocrine carcinoma; skin; malignancy; 
outcome.
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The eponym Merkel cell carcinoma (MCC) refers to a 
rare, poorly-differentiated, aggressive primary neuro-
endocrine skin cancer with Merkel cell polyomavirus 
(MCV) association.
In this review we sought to outline and summarize 
the data for this rare type of skin cancer, focusing espe-
cially on post-transplant cases. Furthermore, we sought 
to introduce the principles of managing this clinically 
challenging skin tumour, and to illustrate the effects that 
post-transplantation states have on the behaviour of MCC 
and how they reflect its line of treatment and prognosis.
OVERVIEW OF MERKEL CELL CARCINOMA 
The histological entity of MCC was first founded when 
Toker described 5 original cases in 1972 (1). Later, 
dense neurosecretory granules in the cytoplasm of the 
tumour cells identified the tumour as a neuroendocrine 
carcinoma. 
Histologically, the tumour is a dermal-based lesion 
with repeated extensions to underlying subcutaneous 
tissue. The tumour is composed of monotonous small 
round blue cells with sparse cytoplasm and abundant 
mitoses (2). Diagnosis is based on typical histology 
representation on haematoxylin-eosin-stained slides 
together with the results of immunohistochemistry 
(3), positivity for cytokeratin 20 (CK-20) and negative 
staining for thyroid transcription factor 1 (TTF-1). 
Furthermore, the tumour expresses both epithelial 
and neuroendocrine markers, and thus exhibits both 
epithelial and neuroendocrine differentiation (4). As 
the histology bears resemblance to small round-cell tu-
mours, differential diagnosis can be difficult. MCC can 
be classified into 3 distinct subtypes; intermediate sub-
type, which is the most frequent histological subtype, 
followed by trabecular and small-cell types. However, 
the clinical significance of subtyping is minimal. 
Clinically MCC usually presents with a non-tender, 
rapidly growing red/pink or blue skin lesion. In the 
early stages it is usually mistaken for a benign lesion, 
however, larger lesions have an unmistakably malig-
nant appearance (Fig. 1). The tumour may grow to a 
considerable size in just a few months and be locally 
invasive with high metastatic potential. The tumours 
are staged according the American Joint Committee 
on Cancer (AJCC) staging system, which takes into 
consideration the microscopic examination of sentinel 
node biopsies (SLNB). 
Although generally considered as an aggressive tu-
mour, with a high mortality rate (5), MCCs can have a 
variable clinical course. Outcome data stratified by tu-
mour size, nodal status and distant metastasis show the 
majority of MCC patients have a relatively good 5-year 
outcome; approximately 60% of patients with negative 
sentinel lymph nodes are alive after 5 years, and for 
those with positive nodal status, the 5-year survival is 
over 40% (6). Some clinical and pathological prognostic 
markers are associated with a poor prognosis, compri-
sing male sex, older age (7), increased tumour size (8) 
and an immunocompromised state. However, the most 
important prognostic marker is the presence or absence 
of metastatic dissemination to the local lymph basin (8). 
Apart from in the Nordic countries, the overall 
incidence rates of MCC in men are higher than for 
Post-transplant Merkel Cell Carcinoma
Virve KOLJONEN1,3, Helka SAHI2, Tom BÖHLING2 and Heikki MÄKISALO3 
Departments of  1Plastic Surgery, 2Pathology, and 3Transplantation and Liver Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
443Post-transplant Merkel cell carcinoma
women (9). Although MCC is rare, with an incidence 
of approximately 0.6 cases per 100,000 person-years 
(9), markedly increasing incidences have been reported 
globally. Over a relatively short period, of decades, the 
age-adjusted incidence increased 8% in the USA (10). 
Advances in diagnostics and the increase in elderly 
age-groups and sun exposure underlie this phenomenon.
Primary risk factors for MCC include immuno-
senescence of advancing age, white race, various im-
munocompromised states and cancer-related immune 
deficiency. MCC is principally a disease of fair-skinned 
elderly individuals, with a mean age at diagnosis of ap-
proximately 75 years (5). The tumours usually occur on 
sun-damaged skin of the head and neck and the extre-
mities, offering indirect evidence for UV exposure as 
an aetiological factor. The specific immunodeficiency-
related risk factors include UV-induced immunosup-
pression, organ transplantation, HIV/AIDS, and autoim-
mune diseases. Usually an immunocompromising state 
precedes MCC if it occurs before the age of 50 years 
(11). Another well-recognized feature is the tendency 
of MCC to occur in association with other primary tu-
mours, mostly skin and lymphohaematopoietic cancers 
and, in particular, B-lymphoproliferative disorders (12). 
As recently as 2008, a new polyomavirus with dou-
ble-stranded DNA, named Merkel cell polyomavirus 
(MCV) was discovered (13) (Fig. 2). MCV is a com-
mon, if not ubiquitous, human infection (14). Accumu-
lated data indicate that MCV does not secondarily infect 
tumour cells. Firstly, the virus is integrated clonally into 
the genomes of MCC primary tumours and their meta-
stases (13). Secondly, the large T (LT) antigen, an early 
gene encoded by MCV, is truncated by MCC-specific 
mutations and expressed continuously. Truncation ena-
bles the LT antigen to inhibit the retinoblastoma tumour 
suppressor protein to prevent lytic viral replication that 
would otherwise damage the cancer cells (15). Without 
the crucial truncating mutations, the traces of MCV in 
various non-cancerous and cancerous tissues represent 
a passenger virus without carcinogenic properties. 
International Agency for research on Cancer (IARC) 
released a consensus statement in 2013 declaring the 
direct causal nature of MCV (16).
The late genes of MCV encode proteins that form 
the viral capsid required for the initial MCV infection. 
They are not expressed in MCC tumours, and thus have 
no role in tumour maintenance. The small T antigen, 
also a late gene of the MCV genome, is expressed in 
MCC tumours and acts downstream in the mammalian 
target of rapamycin (mTOR), a member of the phospha-
tidylinositol 3-kinase (PI3K) cell survival pathway, 
signalling pathway implicated in the regulation of cell 
growth and proliferation (17–19). The PI3K pathway 
is, in fact, up-regulated in MCV-positive MCCs, which 
can potentially lead to suppression of p53 protein 
expression (18). Mutations that activate the PI3KCA 
gene are found in 10% of MCC tumours, most often in 
MCV-negative ones. Although it is debatable whether 
expression of ST viral oncoproteins is required for MCC 
tumour progression as crucially as LT expression, the 
mTOR pathway seems to plays a fundamental role in 
the pathogenesis of MCC (20, 21). 
Fig. 2. Example of Merkel cell polyomavirus detection by immuno-
histochemistry. The Merkel cell polyomavirus is expressed by nearly 100% 
of the tumours cells. Negative staining consists of stromal cells, lymphocytes 
and endothelial cells. Original magnification ×200.
Fig. 1. Typical Merkel cell carcinoma presentation on the head. The tumour 
presents as solitary nodule with a red-to-purple erythematous colour.
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MERKEL CELL CARCINOMA AFTER ORGAN 
TRANSPLANT
Merkel cell carcinoma and immune surveillance
MCC is sensitive to boosts in immune function and 
surveillance. Case reports describe the spontaneous 
regression of MCC tumours after biopsy or cessation of 
immunosuppression, constituting 1.4% of all reported 
MCC cases (22). Administration of immunosuppressive 
medication has, in some cases, led to swift development 
of MCC tumour in previously immunocompetent hosts. 
It was thought that the duration of immunosuppressive 
therapy is an important co-factor for MCC development, 
but the MCC development succeeding immunosuppres-
sion can be rapid in a favourable host (23). 
MCV-specific T-cell responses detected in the periphe-
ral blood of MCC patients are characterized by CD4+ 
helper cells, which react to a broad range of peptides 
derived from viral capsid and oncoproteins (24). IgG 
antibodies against ST and LT are also relatively specific 
to MCC: they are found in 40.5% of MCC patients, but in 
only 0.9% of healthy controls (25). The levels of LT and 
ST antibodies correlate to tumour mass, and increase in 
the event of spread or metastasis of MCC (25). However, 
surveillance for MCV infection is not mediated only by 
humoral immunity and CD4+ Th1-cells, but also by cell-
mediated immunity. MCV-specific CD8+ T-lymphocytes 
are found in the peripheral blood in over half of MCV-
positive MCC patients, increasing with disease progres-
sion and decreasing with successful MCC treatment (26). 
In addition, MCV-positive tumours contain significantly 
increased numbers of tumour-infiltrating CD8+ ad CD3+ 
lymphocytes, NK-cells, macrophages and Tregs (FoxP3+) 
compared with virus negative tumours (27, 28). The num-
ber of CD8+ lymphocytes correlates with a favourable 
prognosis of MCC (27, 29).
MCC tumour cells employ certain mechanisms to 
evade the tumour surveillance by tumour-infiltrating 
lymphocytes (TILs). The loss of vascular E-selectin 
expression, an important factor in T-cell entry to the 
skin, correlates with poor intra-tumoural CD8+ infiltra-
tion and prognosis in MCC tumour cells (30). Decreased 
activity of TILs in MCC is seen as decreased expression 
of co-stimulatory signal molecules, as well as expres-
sion of certain T-cell exhaustion markers (31). These 
findings suggest that the restriction of T-cell entry into 
the tumour and reductions in T-cell function might be 
considerable and even targetable forms of immunoeva-
sion in MCC.
Post-transplant Merkel cell carcinoma 
In 1999 Penn & First (32) observed a connection bet-
ween therapeutic immunosuppression and MCC. They 
reported 41 MCC cases in the Cincinnati Transplant Tu-
mor Registry. Few epidemiological studies address the 
incidence of post-transplant MCC (Table I). Recently, 
epidemiological knowledge increased markedly, when 
Clarke et al. (33) published the so-far largest number 
of MCCs in a defined cohort of organ transplant re-
cipients (OTRs). They showed that the overall risk of 
MCC was increased 23.8-fold and adjusted risks are 
highest among older recipients with increased time 
since transplantation, and varies by organ type. The 
earlier reports show that post-transplant incidence of 
MCC is significantly increased and varies broadly ac-
cording to the research institute and the transplanted 
organ. Solid-organ transplantation carries a general 
4.95-fold increase for MCC (34) and MCC accounts 
for < 5% of all skin cancers in OTRs (35). Among 
renal-transplant recipients, the standardized incidence 
ration (SIR) of MCC varies from 52 to 66 (36, 37), in 
liver transplant recipients it is 182 (37), among heart 
Table I. The main findings of epidemiological cohort studies on Merkel cell carcinoma in organ transplant recipients (OTRs) patients. 
The standardized incidence ratios (SIRs) are obtained by dividing the number of cases in the study population with the expected number 
of cases in the reference population
Reference Study population
Cases, 
n Reference population SIR (95% CI)
Mean age, 
years
Clarke et al. (33) Scientific Registry of US Transplant Recipients
Kidney OTRs (n = 111,775) 70 13.8 n/a
Liver OTRs (n = 40,238) 15 8.4 (0.3–1.1) n/a
Heart/OTRs (n = 17,693) 20 20.8 (0.9–2.4) n/a
All other OTR (n = 19,792) 5 6.7 (0.2–1.2) n/a
Krynitz et al. (37) Swedish transplant registry 1970–2008 Swedish population
Kidney OTRs (n = 7,952) 6 52 (19–113) n/a
Liver OTRs (n = 1,221) 2 182 (22–656) n/a
Heart/lung OTRs (n = 1,012) 2 121 (3.1–671) n/a
Na et al. (38) Australian transplant registry 1987–2006 Australian population
Heart/lung OTRs (n = 2,718) n/a 103 (60–166) n/a
Koljonen et al. (36) Finnish transplant registry 1967–2005 Finnish population
Kidney OTRs (n = 4,200) 3 66 (14–194) 59 
Penn & First (32) Cincinnati Transplant Tumor Registry 1968–1998
All OTRs (n = 10,955) 41 n/a n/a 53 
n/a: not available.
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transplant recipients 103 (38), and among heart/lung 
recipients 121 (37). In this respect, MCC represents 
a serious complication among immunocompromised 
patients, as the risk of MCC increases 15-fold over 
that of the general population (39). 
The initial 41 OTR MCC patients reviewed by Penn 
& First (32) were young, mean age 53 years and the 
course of the disease was more aggressive compared 
with the general MCC population. Since then, this no-
tion has been confirmed repeatedly. Paulson et al. (40) 
demonstrated in a heterogeneous cohort of 41 individu-
als with multiple forms of systemic immunosuppression 
including 12 OTRs, that immunosuppression leads to 
an increased chance of developing MCC and poorer 
MCC-specific survival. Later on, Arron et al. (41) 
showed, with a cohort of 1 liver, 3 lung, and 4 kidney 
transplant recipients, that besides being younger than 
average, the OTR-MCC patients had an increased risk 
of tumour progression, all-cause mortality and MCC-
specific death. 
The existing literature contains more case reports than 
epidemiological studies; the majority of the case report 
patients are male and their mean age at diagnosis is 57 
years (age range 25–72 years) with a mean latency of 
6 years (range 2–27 years) (Table SI and SII1).
To the best of our knowledge, only one study has 
addressed the occurrence of MCV in the MCC tumours 
of OTRs, and the occurrence is low (36). MCV is ex-
pressed with a higher frequency in basal cell carcinoma 
and squamous cell carcinoma samples of the OTRs 
(42). In renal OTRs, 7% of the saliva samples and 21% 
of the oral biopsies carried MCV DNA (43). MCV 
viruria was evident in 30% of renal OTRs (44, 45). In 
transbronchial biopsies from lung transplant recipients 
MCV was found in 34%, with a relatively high virus 
copy number, but not differing from native lungs (46). 
Prevention and treatment 
Treatment of MCC is multi- and interdisciplinary. In 
2015, a new European consensus guideline for diagnosis 
and treatment of MCC was published (2).
The management of skin cancer in OTR requires a 
multidisciplinary approach, especially for high-risk 
MCC patients. Each case should be discussed in the 
multidisciplinary tumour board. The involvement of 
transplant team, plastic and ENT surgeons, pathologists, 
medical oncologist and radiation oncologist cover all 
aspects of diagnosis and care of MCC patient. 
Lifestyle modifications after organ transplant, sun 
protection and sunscreen use, suggested to all OTRs 
against skin malignancies, are also advisable in the 
prevention of MCC (47). Regular total body skin exa-
minations for new skin lesions and increasing the skin 
cancer awareness reduces skin cancer mortality and 
may improve the quality of life (48). 
There are no guidelines for the treatment of post-
transplant MCC, due to its rarity. However, the general 
treatment guidelines for MCC are applicable to both 
non-OTR and OTR MCC patients. The guidelines 
for MCC adhere to the guidelines for high-risk post-
transplant non-melanoma skin cancers (49). 
Surgery is the foundation of the treatment. Localized 
disease is treated with excision with pathologically 
clear margins. Current recommendations are based on 
the clinical size of the primary tumour: excision with 
1-cm margins for tumours ≥ 2 cm, and excision with 
2-cm margins for tumours > 2 cm (50). Although there 
is no solid conclusion on the width of the surgical 
margins, the excision of the fast-grown tumour may 
result in a large defect, resulting in a functional and 
aesthetic defect, especially if the tumour occurs in the 
face. However, the anatomical location of the tumour 
or the large size should not restrict adequate excision, 
due to multiple reconstructive options available (51). 
Sentinel lymph node biopsy (SLNB) is recommended 
for all MCC patients, if the disease is not systemic at 
diagnosis (52). SLNB improves diagnostics and prog-
nostic precision; approximately 30% of MCC cases 
that are estimated to be local are clinically present with 
microscopic nodal metastases detected in histological 
examination. SLNB is reliable and repeatable technique 
in MCC. However, what is SLNBs predictive value, 
remains deciphered as it seems that SLNB status do 
not predict either recurrence or survival (53), nor it is 
an independent predictor of survival in head and neck 
MCC (54). Currently other ways of staging MCC are 
under investigation. The most promising seems to be 
the FDG–PET (55, 56). 
When tumour spread to local lymph nodes is clini-
cally and pathologically verified, a completion lymph 
node dissection should be considered. However, recent 
studies have shown that radiation therapy alone can 
provide regional control rate comparable to comple-
tion lymph node dissection for both microscopic and 
palpable lymph node disease (57). Treating the primary 
tumour in inoperable patients with radiotherapy alone 
leads to acceptable results (58), and when the comple-
tion lymph node dissection is too risky for the patient, 
radiotherapy of the lymph node basin can be considered 
(59). Administration of adjuvant radiotherapy dimi-
nishes recurrences, but does not increase the overall 
survival (60). Controversial findings in a Surveillance 
Epidemiology and End Results (SEER)-based popu-
lation suggest that the increase in survival seen with 
adjuvant radiation therapy is not disease-specific and 
might be a result of selection bias. 
Treatment of systemic MCC is palliative. Postopera-
tive chemotherapy has not been proven effective despite 
trials with various chemical compounds. The most 1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2284
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frequently administered chemotherapeutic agents are 
those used in other neuroendocrine carcinomas, most 
commonly polychemotherapy with cisplatin, etoposide 
and/or doxorubicin (61, 62).
Reduction in immunosuppression to the lowest level 
while maintaining good graft function should be consi-
dered in all OTR MCC patients, as it is for transplant 
recipients with aggressive squamous cell carcinoma or 
melanoma (63). Conversion from calcineurin inhibitors 
to a regimen based on mTOR inhibitors that exert an 
anti-angiogenic and antitumor effect may be recom-
mended. Case reports have reported transient remission 
of metastatic MCC after cessation of cyclosporine (64). 
Inhibition of the mTOR pathway in human MCC cell 
lines induces autophagy and cell death (65). Recently 
it has been shown that some 10% of the MCC tumours 
have mutations in the PIK3CA gene and the cell lines 
with this mutation are particularly sensitive to inhibition 
of the PI3K/mTOR pathway (66). A few clinical cases 
have reported the use of rapamycin in the treatment of 
MCC in OTR, although the switch to rapamycin did 
not offer survival advantage (67), probably due to the 
fact that the switch was made after systemic dissemina-
tion. Rapamycin therapy is associated with significant 
wound-healing problems, thus a switch to rapamycin 
should be scheduled after the necessary operations. 
Capecitabine, is a prodrug of 5-fluoruracil and was 
first approved for the treatment of metastatic breast 
and colorectal cancers. Later it was noted that patients 
on capecitabine medication for metastatic breast and 
colon cancers presented with irritation and inflamma-
tion of actinic keratoses that led to the resolution of 
these precancerous lesions (68). Succeeding trials have 
shown that oral capecitabine may lead to remission of 
squamous cell carcinoma of the skin (69). Currently 
only sporadic papers have reported the use of capeci-
tabine in MCC (56, 70, 71). The numbers are too small 
to draw conclusions on the effect on MCC. 
FUTURE TREATMENTS
Perhaps, the improvement most likely to occur in 
the near future is the paradigm shift from mutilative 
surgical treatment to non-surgical treatment of MCC. 
MCC is a radio-sensitive tumour, and recent studies 
have succeeded in treating both primary and regionally 
metastatic MCCs (59, 72). How this will translate to 
the OTR MCC patients, remains to be determined. 
MCC tumour cells contain activating mutations of 
c-KIT that mark susceptibility for the tyrosine kinase 
inhibitor imatinib mesylate in other neuroendocrine 
carcinomas (73). MCC cell growth has been impaired 
in vitro with the administration of imatinib methylate, 
but clinical trials have not replicated the effect (69). 
Other mechanism-based treatment options currently 
tested in clinical trials include the tyrosine kinase 
receptor inhibitors pazopanib and cabozantinib, the 
somatostatin analogue ocreotide, and the surviving 
inhibitor YM-155 (74). 
High levels of antibodies against viral capsid proteins 
improve the prognosis of MCC (75). Thus, the use of 
MCV capsid protein particles as vaccine against MCC 
has been suggested (14). Vaccinations for at-risk groups 
are not feasible, as the viral infection occurs at an early 
age, and even though strong humoral responses are as-
sociated with better survival, the cancer progression is 
not inhibited. No studies have been conducted regarding 
the chemoprevention of MCC with retinoids in OTR 
patients. Treatment protocols remain to be established 
for other non-melanoma cancers as well, acitretin being 
the most favourable retinoid in OTR cases according 
to the current view (76). Retinoids have been reported 
to directly activate the PI3K/Akt/mTOR pathway in 
different cell types. Considering the PI3K-activating 
mutations detected in MCC, the effects of retinoids in 
terms of MCC prevention are difficult to predict. 
Several immunological treatment options have recent-
ly been found effective in curbing MCC cell proliferation 
in vitro. Interferon-α and -β subtypes restrict tumour cell 
proliferation and decrease lymphotoxin alpha expression, 
but in vivo treatments have led to unfortunate adverse ef-
fects (77). Intralesional interferon-β treatment is the most 
promising of possible interferon therapies (74). Adminis-
tering interleukin-2 and interleukin-15 increases cytokine 
production, activates T-cells, increases T-regulatory cell 
count and diminishes tumour cell count (31). 
Advances in the treatment of melanoma are also 
serving as ground breakers in managing metastatic 
MCC. Current clinical trials include treatments with 
an anti-PD-L1 molecule and the autologous transfer 
of MCV-specific CD8+ lymphocytes, both of which 
have shown promising results in melanoma. In another 
recruiting clinical trial, MCC patients are treated with 
ipilimumab, which is already approved for melanoma 
by the US Food and Drug Administration (FDA). 
CONCLUSION
In conclusion, although the occurrence of MCC in 
individual OTR is very rare, the morbidity and mor-
tality brought on by MCC warrants active screening. 
When a rapidly growing nodule arises on a skin of an 
immunosuppressed person, a tissue biopsy is called for. 
Even younger patients (< 50 years) should be inspected 
for skin lesions with MCC in mind. No preventive 
measures against MCV infection or MCC are in use 
for OTR patients. In the case of MCC, transplant units 
are advised to work as a part of the multidisciplinary 
team, and the doses of immunosuppressive medication 
should be re-evaluated and possibly lowered. In the 
future, MCV-specific biologic cancer therapies might 
benefit MCC OTR patients in particular. 
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